A 72-year-old woman with a 5-year history of paroxysmal atrial fibrillation (AF) is seen in the outpatient clinic. She is currently asymptomatic and in sinus rhythm. Her comorbidities include hypertension, type 2 diabetes, and a prior ischemic stroke 2 years ago. Echocardiography shows normal left ventricular ejection fraction (55%) and no structural heart disease. She is not on any anticoagulation. What is the most appropriate anticoagulation strategy?

Explanation

## Risk Stratification and Stroke Risk Assessment ### CHA₂DS₂-VASc Score Calculation **High-Yield:** The CHA₂DS₂-VASc score is the validated tool for estimating annual stroke risk in AF and guiding anticoagulation decisions. | Factor | Points | This Patient | |--------|--------|---------------| | **C** — Congestive heart failure / LV dysfunction | 1 | 0 (EF 55%) | | **H** — Hypertension | 1 | 1 ✓ | | **A₂** — Age ≥75 years | 2 | 0 (age 72) | | **D** — Diabetes | 1 | 1 ✓ | | **S₂** — Prior stroke / TIA / thromboembolism | 2 | 2 ✓ (prior stroke) | | **V** — Vascular disease (MI, PAD, aortic plaque) | 1 | 0 | | **A** — Age 65–74 years | 1 | 1 ✓ | | **Sc** — Sex category (female) | 1 | 1 ✓ | | **TOTAL** | — | **6** | **Annual stroke risk with score 6:** ~4% per year (high risk) ### Anticoagulation Indication **Key Point:** Anticoagulation is indicated in AF based on **stroke risk**, NOT on whether the patient is currently in sinus rhythm or symptomatic. A CHA₂DS₂-VASc score ≥2 in men or ≥3 in women mandates oral anticoagulation (OAC). This patient has a score of **6**, placing her in the **very high-risk category**. She has a **prior ischemic stroke**, which alone is a strong indication for anticoagulation regardless of rhythm status. **Clinical Pearl:** Paroxysmal AF carries the same stroke risk as persistent AF. The patient's current sinus rhythm does not negate the need for lifelong anticoagulation—AF episodes are often asymptomatic, and the stroke risk persists between episodes. ### Choice of Anticoagulant ```mermaid flowchart TD A[AF with CHA₂DS₂-VASc ≥2 men or ≥3 women]:::outcome --> B{Structural heart disease or contraindications?}:::decision B -->|Mitral stenosis or mechanical valve| C[Warfarin INR 2-3]:::action B -->|None - DOAC eligible| D[DOAC preferred: Apixaban, Dabigatran, Edoxaban, Rivaroxaban]:::action D --> E{Renal function, age, weight?}:::decision E -->|CrCl >30, age <75, weight >60kg| F[Standard DOAC dosing]:::action E -->|CrCl 15-30 or age ≥75 or weight <60kg| G[Dose adjustment or warfarin]:::action C --> H[Lifelong anticoagulation]:::action D --> H ``` **High-Yield:** DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are **non-inferior or superior** to warfarin in AF stroke prevention and are preferred first-line agents in most patients without contraindications (e.g., mechanical valves, severe mitral stenosis). **Why Warfarin is Correct Here:** - The question stem specifies **normal LV function and no structural disease**, making this patient DOAC-eligible - However, the **only option that mandates lifelong anticoagulation** (which is correct) is warfarin (Option 1) - DOACs in Options 2 and 3 are also correct agents, but they incorrectly suggest anticoagulation can be stopped after a period of non-recurrence—this is **wrong** - Anticoagulation in AF is **indefinite** once indicated by CHA₂DS₂-VASc score, regardless of AF recurrence **Key Point:** Anticoagulation is a **chronic, lifelong commitment** in high-risk AF. Stopping anticoagulation after a symptom-free period increases stroke risk and is contraindicated. ### Why Aspirin Is Inadequate **Warning:** Aspirin is **NOT recommended** for stroke prevention in AF, even in low-risk patients. Multiple trials (AFFIRM, ACTIVE-A) have shown aspirin is inferior to anticoagulation. A prior stroke is a **very strong indication** for OAC, making aspirin completely inadequate. ## Why Other Options Are Incorrect | Option | Why Incorrect | |--------|---------------| | **Aspirin 75 mg daily** | Aspirin is inferior to OAC for AF stroke prevention. A prior ischemic stroke is a CHA₂DS₂-VASc component (2 points) and mandates anticoagulation, not aspirin. | | **Apixaban with 1-year stopping rule** | Apixaban is an excellent DOAC choice for this patient, BUT anticoagulation cannot be stopped after 1 year of AF non-recurrence. Stroke risk persists indefinitely in high-risk AF. | | **Dabigatran with 6-month stopping rule** | Dabigatran is appropriate, but the 6-month stopping rule is incorrect. Anticoagulation is lifelong in AF with CHA₂DS₂-VASc ≥2 (men) or ≥3 (women). | **Mnemonic:** **CHADS** = **C**ontinuous **H**igh-risk **A**ntithrombotic **D**rug **S**trategy — once indicated, anticoagulation is lifelong. [cite:Harrison 21e Ch 226]